Merck EPS - Earnings per Share 2006-2019 | MRK

Merck annual and quarterly earnings per share history from 2006 to 2019. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
  • Merck EPS for the quarter ending June 30, 2019 was $1.03, a 63.49% increase year-over-year.
  • Merck EPS for the twelve months ending June 30, 2019 was $3.57, a 614% increase year-over-year.
  • Merck 2018 annual EPS was $2.32, a 166.67% increase from 2017.
  • Merck 2017 annual EPS was $0.87, a 38.3% decline from 2016.
  • Merck 2016 annual EPS was $1.41, a 9.62% decline from 2015.
Merck Annual EPS
2018 $2.32
2017 $0.87
2016 $1.41
2015 $1.56
2014 $4.07
2013 $1.47
2012 $2.00
2011 $2.02
2010 $0.28
2009 $5.65
2008 $3.63
2007 $1.49
2006 $2.03
2005 $2.10
Merck Quarterly EPS
Q2 2019 $1.03
Q1 2019 $1.12
Q4 2018 $0.69
Q3 2018 $0.73
Q2 2018 $0.63
Q1 2018 $0.27
Q4 2017 $-0.38
Q3 2017 $-0.02
Q2 2017 $0.71
Q1 2017 $0.56
Q4 2016 $-0.20
Q3 2016 $0.78
Q2 2016 $0.43
Q1 2016 $0.40
Q4 2015 $0.35
Q3 2015 $0.64
Q2 2015 $0.24
Q1 2015 $0.33
Q4 2014 $2.51
Q3 2014 $0.31
Q2 2014 $0.68
Q1 2014 $0.57
Q4 2013 $0.27
Q3 2013 $0.38
Q2 2013 $0.30
Q1 2013 $0.52
Q4 2012 $0.30
Q3 2012 $0.56
Q2 2012 $0.58
Q1 2012 $0.56
Q4 2011 $0.48
Q3 2011 $0.55
Q2 2011 $0.65
Q1 2011 $0.34
Q4 2010 $-0.16
Q3 2010 $0.11
Q2 2010 $0.24
Q1 2010 $0.09
Q4 2009 $2.63
Q3 2009 $1.61
Q2 2009 $0.74
Q1 2009 $0.67
Q4 2008 $0.78
Q3 2008 $0.51
Q2 2008 $0.82
Q1 2008 $1.52
Q4 2007 $-0.76
Q3 2007 $0.70
Q2 2007 $0.77
Q1 2007 $0.78
Q4 2006 $0.22
Q3 2006 $0.43
Q2 2006 $0.69
Q1 2006 $0.69
Q4 2005 $0.50
Q3 2005 $0.65
Q2 2005 $0.33
Q1 2005 $0.62
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $217.785B $42.294B
Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies and animal health products, they work with customers and operate the countries to deliver innovative health solutions. The Company also demonstrate their commitment to increasing access to health care through far-reaching policies, programs and partnerships. Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $346.681B 15.10
Roche Holding AG (RHHBY) Switzerland $237.118B 0.00
Novartis AG (NVS) Switzerland $205.270B 17.65
Pfizer (PFE) United States $191.651B 11.29
Novo Nordisk (NVO) Denmark $126.560B 21.00
AstraZeneca (AZN) United Kingdom $112.309B 22.51
Eli Lilly (LLY) United States $106.700B 19.91
Sanofi (SNY) France $104.896B 12.93
GlaxoSmithKline (GSK) United Kingdom $99.695B 12.60
AbbVie (ABBV) United States $95.259B 7.63
Bristol-Myers Squibb (BMY) United States $76.848B 10.90
Bayer (BAYRY) Germany $66.954B 9.76
H Lundbeck (HLUYY) Denmark $8.015B 11.57